All Molecular Partners articles
-
ArticleLogic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
-
ArticleInside AACR: DARPins take aim at hard-to-treat tumours
Amelie Croset of Molecular Partners breaks down the DARPin developments featured at AACR 2025 – from targeted radiopharmaceuticals to precision-engineered immune cell engagers.